AQP4 and neuromyelitis optica: The marked NMO pathology seen in CD59−/− rats following AQP4-IgG administration contrasts with the conclusions of Saadoun and Papadopoulos [27], who concluded that complement inhibitors, including CD59, are not protective against complement injury in CNS tissues.